Horizon Europe European Union
Neutral-Atom Platform Technologies
This action aims to establish European leadership in neutral-atom quantum simulation and digital quantum computing by delivering: • Fully programmable industry-ready quan…
Horizon Europe · European Union
Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
Open
The EU's Horizon Europe programme expects to make 4 awards of €9 million – €10 million each, from a total budget of €37.3 million. Applications close on 17 Feb 2027 (EU calls usually close at 17:00 Brussels time). Organisations in EU member states and Horizon Europe associated countries such as Türkiye can usually take part; the topic conditions control.
- Deadline
- 17 Feb 2027 (in 94 days)
- Grant amount
- €9 million – €10 million per project
- Total budget
- €37.3 million
- Funding rate
- 100% of eligible costs Standard rule for this programme; the call can differ.
- Total budget
- €37.3 million
- Expected awards
- 4
- Type of action
- HORIZON Research and Innovation Actions · HORIZON Action Grant Budget-Based
- Likely applicant types
- Companies, SMEs / start-ups, Non-profits, Universities & research, Public bodies From source categories or programme rules; the call decides.
- Funder
- Horizon Europe (HORIZON)
- Reference
- HORIZON-HLTH-2027-01-DISEASE-06
- Call
- HORIZON-HLTH-2027-01
- Last checked
- 14 Nov 2026
Expected outcome
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:
• The scientific and clinical communities have a better understanding of and access to experimental monoclonal antibodies for the prevention and treatment of emerging or re-emerging viral infections, as well as for further clinical investigation.
• Candidate monoclonal antibody therapies are available to treat patients for emerging and re-emerging viral infections, increasing therapeutic options for clinical deployment in case of an epidemic or pandemic.
Scope
Infectious diseases remain a major threat to health and health security in the EU and globally. Viral disease emergence is already being accelerated by climate change, and thus a proactive approach to the development of antiviral prophylactics and therapeutics in preparedness for future infectious disease outbreaks is needed. The capacity to produce antibodies that can target new variants and rapidly increase production would serve as an essential preparedness strategy against future health threats, whether from infectious disease epidemics or pandemics.
This topic contributes to strengthening the Research and Innovation ecosystem within the EU and supports the implementation of the European Medical Countermeasures Strategy [1] .
Applicants should explicitly state in their proposal which of the following Flaviviruses is targeted and the proposed work should address only this specific Flavivirus. The proposed work should aim to advance the development of existing prophylactic and therapeutic monoclonal antibody candidates targeting exclusively one of the following Flaviviriuses:
Read the full text
• Dengue Virus
• Tick-borne Encephalitis Virus
• Japanese Encephalitis Virus
• West Nile Fever Virus
• Yellow Fever Virus
• Zika Virus
Proposals should focus on antibodies produced or derived from a single cell clone through recombinant expression, such as B-cell derived antibodies, hybridoma derived antibodies and nanobodies.
Proposals should thus aim to diversify and accelerate the global prophylactic and therapeutic research and development portfolio for emerging and re-emerging viral infections, and to strengthen the leading role of the EU in prophylactic and therapeutic research and development.
Proposals should address all the following research areas:
• If necessary, finalisation of the in-vitro characterisation of existing monoclonal antibody candidates with regard to target specificity, epitope recognised, and their ability to impair or inactivate viral functions.
• In-vivo tests in at least one animal model or, if available in humanised immune system animal models, to demonstrate the protective function of the monoclonal antibodies deemed sufficient for moving to first clinical trials.
• If requested by regulators as pre-requisite for clinical studies, in-vivo tests in a non-human primate model.
• Evaluation of Antibody-Dependent Enhancement (ADE) risk where scientifically relevant.
• Production of batches of the most promising antibody candidates according to the Good Manufacturing Practices (GMP) [2] .
• First in human clinical safety studies demonstrating a clear regulatory pathway for market authorisation. Attention should be paid to critical biological and social factors such as sex, age, ethnicity and disability.
Participation of third countries where viruses addressed in the proposal are endemic or where outbreaks have occurred or are ongoing is encouraged.
The participation of start-ups, micro, small and medium-sized enterprises (SMEs) [3] is encouraged…
Who can apply
Consortium of at least 3 independent legal entities from 3 different EU Member States or associated countries, at least one in a Member State (Horizon Europe standard rule).
Applicant categories are a starting point. The official call decides eligibility.
Topics
Clinical development, Phase I Clinical trials Dengue Disease control Drug development, clinical phases Emerging Epidemics Epidemiology Infectious diseases Public health and epidemiology Viruses West Nile GMP Yellow Fever Zika encephalitis japanese monoclonal tick-borne
Timing
Single-stage call. Next deadline 2027-02-17. The portal states the exact cut-off time (EU calls usually close at 17:00 Brussels time).
How to apply
- Read the full topic on the Funding & Tenders Portal: expected outcome, scope, type of action and the topic conditions, including any country restrictions.
- Register each participating organisation in the Funding & Tenders Portal to get a PIC.
- Consortium of at least 3 independent legal entities from 3 different EU Member States or associated countries (Horizon Europe standard rule; Türkiye is associated). Confirm in the topic conditions.
- Prepare Part A (administrative forms and budget, completed in the portal) and Part B (the technical description on the official template for this type of action).
- Submit in the portal before the cut-off time on the deadline day. Late submissions are not accepted.
From the call text
- Who can apply
- Not stated in the call text we hold — check the official page
- Company stage
- Not stated in the call text we hold — check the official page
- Single applicant or consortium
- Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
- Where applicants must be based
- Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
- Where to apply
- Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
Where these facts come from
| Fact | Value | How we know | Taken from the source |
|---|---|---|---|
| Deadline | 17 February 2027 “Single-stage call. Next deadline 2027-02-17. The portal states the exact cut-off time (EU calls usually close at 17:00 Brussels time).” | official data field | 15 Nov 2026 |
| Amount per applicant | Unknown — not stated in the source we hold | unknown | — |
| Total budget | €37.3 million | official data field | 15 Nov 2026 |
| Funding rate | 100% of eligible costs | programme standard rule | 15 Nov 2026 |
| Who can apply | Consortium of at least 3 independent legal entities from 3 different EU Member States or associated countries, at least one in a Member State (Horizon Europe standard rule). | programme standard rule | 15 Nov 2026 |
| Where to apply | Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route. | read from the official text | 15 Nov 2026 |
Official sources
Facts on this page come from the funder’s official data, taken on 14 Nov 2026. The funder's own documents, including later amendments, always take precedence.
More from Horizon Europe
Horizon Europe European Union
Next-Generation QKD Systems
This action will strengthen Europe's strategic autonomy in quantum-secure communications by advancing core QKD technologies and integration capabilities. Expected results…
Horizon Europe European Union
Quantum Experimental Pilot Lines for Quantum Technologies
This action will strengthen Europe's leadership and strategic autonomy in quantum technologies by advancing experimental pilot line capacities as a vital stepping stone t…
Horizon Europe European Union
Quantum-Testing Infrastructure for Quantum Technologies
This action will establish a pan-European open-access testing and experimentation infrastructure for quantum technologies, enabling systematic validation and certificatio…
Horizon Europe European Union
Superconducting Platform Technologies
This action will consolidate Europe’s position in superconducting quantum computing through: • Establishment of a full-stack superconducting quantum computer aiming at 1.…